Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $28.00

Intellia Therapeutics (NASDAQ:NTLA) had its price objective raised by Citizens Jmp from $21.00 to $28.00 in a research note released on Tuesday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

Several other research firms have also commented on NTLA. Truist Financial reiterated a “buy” rating and set a $14.00 price objective (down from $25.00) on shares of Intellia Therapeutics in a research note on Monday, November 10th. Wells Fargo & Company cut their price target on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Royal Bank Of Canada reduced their price target on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Wedbush decreased their price objective on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Finally, HC Wainwright boosted their target price on Intellia Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Eleven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.59.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $13.15 on Tuesday. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The business has a fifty day moving average price of $12.25 and a 200 day moving average price of $13.10. The stock has a market capitalization of $1.55 billion, a P/E ratio of -3.43 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to the consensus estimate of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm’s revenue was up 78.4% on a year-over-year basis. During the same period in the previous year, the company posted ($1.27) earnings per share. As a group, equities research analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP James Basta sold 10,397 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the sale, the executive vice president owned 101,528 shares of the company’s stock, valued at approximately $935,072.88. The trade was a 9.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the sale, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,051 shares of company stock worth $488,600 in the last 90 days. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC raised its position in Intellia Therapeutics by 154.1% during the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after buying an additional 55,118 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Intellia Therapeutics in the first quarter worth $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after purchasing an additional 38,521 shares during the last quarter. Atria Investments Inc purchased a new position in shares of Intellia Therapeutics during the second quarter worth $96,000. Finally, Intellectus Partners LLC lifted its position in Intellia Therapeutics by 3.8% during the second quarter. Intellectus Partners LLC now owns 85,975 shares of the company’s stock valued at $806,000 after purchasing an additional 3,150 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics News Summary

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds on a second gene‑therapy trial for Intellia — a material de‑risking event that restores clinical momentum for NTLA’s in‑vivo programs and was a direct catalyst for recent rallies. FDA’s lifting of clinical holds sends Intellia upwards
• Positive Sentiment: Multiple analyst upgrades and bullish notes — JonesTrading upgraded NTLA to Buy with a $29 target (large upside), and other firms (Leerink, Wells Fargo) issued bullish commentary that supports higher near‑term sentiment. JonesTrading upgrade / coverage summary
• Positive Sentiment: Royal Bank of Canada raised its price target to $15, reinforcing analyst support after the recent rebound. RBC boosts Intellia price target to $15
• Neutral Sentiment: HC Wainwright slightly trimmed near‑term EPS estimates but kept a Buy rating and a $30 target — a mixed signal (modest near‑term cost pressure acknowledged, long‑term conviction intact). HC Wainwright analyst note
• Neutral Sentiment: Valuation discussion: recent recovery has put NTLA back on investors’ radar but analysts note wide losses and heavy R&D spending; the stock’s rebound raises valuation questions for some investors. A Look At Intellia Therapeutics Valuation
• Negative Sentiment: Canaccord lowered expectations for NTLA — an analyst downgrade to forecasts that can weigh on near‑term sentiment and give holders a reason to take profits after the run‑up. Canaccord lowers expectations

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.